Microdosing study with docetaxel: Clinical pharmacology and pharmacogenetic exploratory research

Not Applicable

• Conditions: Cancer

• Registration Number: JPRN-UMIN000004470
• Lead Sponsor: Saitama Medical University, International Medical Center, Department of Medical Oncology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-10-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients with severe allergy or those who had severe allergy in the past (including that for polysorbate 80). 2)Pregnant patients. Men and women who want to make baby. 3)Ptisnts with active infection. HCV, HBs or HIV positive. 4)Patients with severe complications (interstitial pneumonia or pulmonary fibrosis, renal failure, liver failure, incontrollable diabetes or hypertension). 5)Patients with cardiovascular disease or showing severely atypical electro cardiogram. 6)Patients with gastrointestinal ulcer or related bleeding. 7)Patients with uncontrollable diarrhea. 8)Patients with brain metastasis with any symptoms or those without any symptoms with steroid medication. 9)Patients with pleural fluid or abdominal dropsy which is required medical intervention. 10)Patients who experienced thromboembolism, stroke or pulmonary infarction. 11)Patients who receive operation within 28 days. 12)Patients with inborn hemorrhagic diathesis, coagulation disorder or those with DIC. 13)Patients having anticoagulant including aspirin or warfarin. 14)Patients with continuous steroid therapy. 15)Patients who do not understand this study well. 16)Patients who are not appropriate to participate in the study safely.

Study & Design

• Study Type: Interventional
• Study Design: Not specified